Dr. Trésor Bodjick is a medical doctor with an advanced degree in Vaccinology and Pharmaceutical Clinical Development. He is affiliated to the Clinical Pharmacology and Pharmacovigilance Unit of the University of Kinshasa, which also serves as the National Pharmacovigilance Center of the Democratic Republic of Congo (DRC). With over eight years of experience in clinical research and vaccine pharmacovigilance, his work focuses on advancing public health through rigorous research and data-driven decision-making.

Dr Bodjick has contributed to monitoring several international vaccine clinical trials, including the Ebola vaccine clinical trials in Goma and Boende (DRC). He is passionate about generating best evidence from real world data and intends to focus on Real-world evidence for vaccine safety.

He recently coordinated the implementation of the Cohort event monitoring (CEM) study of adverse events following immunization after vaccination with Mpox vaccines in DRC. He is currently the co-Principal Investigator of the BRAVE (Background Rates of Adverse events for Vaccine Evaluation in Africa) project in DRC and is involved in the coordination of an ongoing Mpox vaccine (LC16m8) effectiveness and safety study in the country.